OBIO · Orchestra BioMed Holdings, Inc.
AI read · Good for OBIO
The AI's read
The change shows B. Riley sees slightly more room for Orchestra BioMed shares and kept its Buy rating. The report gives no new sales, trial results, or company forecast, so the support comes only from the firm's opinion.